Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition

p53, the cellular gatekeeper for growth and division

Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

A System for Stable Expression of Short Interfering RNAs in Mammalian Cells

Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,295

Live or let die: the cell's response to p53

Vousden, K. H., & Lü, X. (2002) · Nature reviews. Cancer · doi:10.1038/nrc864 · Cited by 3,231

p53 is required for radiation-induced apoptosis in mouse thymocytes

Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206

WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis.

El‐Deiry, W. S., Harper, J. W., O'Connor, P. M., Velculescu, V. E., Ce, C., Jackman, J., Pietenpol, J. A., Burrell, M., De, H., & Wang, Y. (1994) · PubMed · Cited by 2,021

Restoration of p53 function leads to tumour regression in vivo

Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820

Inauhzin Sensitizes p53-Dependent Cytotoxicity and Tumor Suppression of Chemotherapeutic Agents

Zhang, Y., Zhang, Q., Zeng, S. X., Hao, Q., & Lu, H. (2013) · Neoplasia · doi:10.1593/neo.13142 · Cited by 23

A highly efficient and eco-friendly method for the synthesis of 1,3-indandione ring-fused 3-oxindoles bearing two contiguous quaternary stereocenters via an aldol reaction in aqueous media

Liu, X., Pan, B., Zhang, W., Yang, C., Yang, J. Y., Shi, Y., Feng, T., Zhou, Y., & Yuan, W. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob02103g · Cited by 23

LYG-202 inhibits the proliferation of human colorectal carcinoma HCT-116 cells through induction of G1/S cell cycle arrest and apoptosis via p53 and p21WAF1/Cip1 expression

Liu, W. Y., Dai, Q., Lu, N., Wei, L., Ha, J., Rong, J., Mu, R., You, Q., Li, Z., & Guo, Q. (2011) · Biochemistry and Cell Biology · doi:10.1139/o10-162 · Cited by 23

Novel anthranilamide-pyrazolo[1,5-a]pyrimidine conjugates modulate the expression of p53-MYCN associated micro RNAs in neuroblastoma cells and cause cell cycle arrest and apoptosis

Ramaiah, M. J., Pushpavalli, S. N. C. V. L., Lavanya, A., Bhadra, K., Haritha, V., Patel, N., Tamboli, J. R., Kamal, Ä., Bhadra, U., & Pal‐Bhadra, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.018 · Cited by 23

An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts

Matsushima, S., Okita, N., Oku, M., Nagai, W., Kobayashi, M., & Higami, Y. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.03.061 · Cited by 23

Discovery of N-aryl-9-oxo-9H-fluorene-1-carboxamides as a new series of apoptosis inducers using a cell- and caspase-based high-throughput screening assay. 2. Structure–activity relationships of the 9-oxo-9H-fluorene ring

Kemnitzer, W. E., Sirisoma, N. S., Jiang, S., Kasibhatla, S., Crogan‐Grundy, C., Tseng, B., Drewe, J. A., & Cai, S. X. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.025 · Cited by 23

Using targeted transgenic reporter mice to study promoter-specific p53 transcriptional activity

Goh, A. M., Lim, C. Y., Chiam, P. C., Li, L., Mann, M. B., Mann, K. M., Ménendez, S., & Lane, D. P. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1114173109 · Cited by 24

Targeting Protein–Protein Interactions in the Ubiquitin–Proteasome Pathway

Gaczynska, M. E., & Osmulski, P. A. (2017) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2017.09.001 · Cited by 24

The roles of mouse double minute 2 (MDM2) oncoprotein in ocular diseases: A review

Jiang, H., Luo, J., & Lei, H. (2022) · Experimental Eye Research · doi:10.1016/j.exer.2021.108910 · Cited by 23

Peptide Activators of the p53 Tumor Suppressor

Zhan, C., & Lu, W. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222577 · Cited by 23

Identification of High Affinity Non-Peptidic Small Molecule Inhibitors of MDM2-p53 Interactions through Structure-Based Virtual Screening Strategies

Bandaru, S., Ponnala, D., Lakkaraju, C., Bhukya, C. K., Shaheen, U., & Nayarisseri, A. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.9.3759 · Cited by 22

Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer

Ren, X., Cui, H., Wu, J., Zhou, R., Wang, N., Liu, D., Xie, X., Zhang, H., Liu, D., Ma, X., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4755 · Cited by 23

N-Acylpolyamine inhibitors of HDM2 and HDMX binding to p53

Hayashi, R., Wang, D., Hara, T. J., Iera, J. A., Durell, S. R., & Appella, D. H. (2009) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2009.10.032 · Cited by 23

Structure and Activity Analysis of Inauhzin Analogs as Novel Antitumor Compounds That Induce p53 and Inhibit Cell Growth

Zhang, Q., Ding, D., Zeng, S. X., Ye, Q.-Z., & Lu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046294 · Cited by 22

TP53 mutant MDM2-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation

Drummond, C. J., Esfandiari, A., Liu, J., Lü, X., Hutton, C., Jackson, J., Bennaceur, K., Xu, Q., Makimanejavali, A. R., Bello, F. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10073 · Cited by 22

The Evolving Role of Companion Diagnostics for Breast Cancer in an Era of Next-Generation Omics

Rosenbaum, J. N., & Weisman, P. S. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.04.021 · Cited by 22

Ubiquitin, SUMO, and Nedd8 as Therapeutic Targets in Cancer

Gâtel, P., Piechaczyk, M., & Bossis, G. (2020) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-38266-7_2 · Cited by 23

Structure and function of MDM2 and MDM4 in health and disease

Zhu, I. Y., Lloyd, A., Critchley, W. R., Saikia, Q., Jade, D., Divan, A., Zeqiraj, E., Harrison, M. A., Brown, C. J., & Ponnambalam, S. (2025) · Biochemical Journal · doi:10.1042/bcj20240757 · Cited by 22

The p53 pathway in vasculature revisited: A therapeutic target for pathological vascular remodeling?

Cui, X., Pan, G., Chen, Y., Guo, X., Liu, T., Zhang, J., Yang, X., Cheng, M., Gao, H., & Jiang, F. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105683 · Cited by 21

Base catalysed domino and self-domino Michael–Aldol reactions: one-pot synthesis of dispirocyclopentaneoxindoles containing multiple chiral stereocenters

Suman, K., & Thennarasu, S. (2015) · RSC Advances · doi:10.1039/c5ra00283d · Cited by 21

An InBr3 catalyzed one-pot three-component synthesis of functionalized spirodihydrofuran oxindoles via intramolecular alkyne carbonyl metathesis

Siddiqui, I. R., Rahila, Shamim, S., Rai, P., Shireen, Waseem, M. A., & Abumhdi, A. A. H. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.09.122 · Cited by 21

Effect of Stapling on the Thermodynamics of mdm2–p53 Binding

Maity, A., Choudhury, A. R., & Chakrabarti, R. (2021) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.1c00219 · Cited by 21

Relationship of the expression levels of XIAP and p53 genes in hepatocellular carcinoma and the prognosis of patients

Li, Z., Han, C., & Feng, J. (2017) · Oncology Letters · doi:10.3892/ol.2017.6681 · Cited by 20

Targeted delivery of a novel palmitylated D-peptide for antiglioblastoma molecular therapy

Li, C. V., Shen, J., Wei, X., Xie, C., & Lu, W. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2011.645162 · Cited by 20

Global Effect of Inauhzin on Human p53-Responsive Transcriptome

Liao, J., Zeng, S. X., Zhou, X. Y., & Lu, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052172 · Cited by 20

Cerium oxide-catalyzed multicomponent condensation approach to spirooxindoles in water

Shrestha, R., Sharma, K., Lee, Y. R., & Wee, Y. (2016) · Molecular Diversity · doi:10.1007/s11030-016-9670-2 · Cited by 20

Structural Basis for Inhibition of the MDM2:p53 Interaction by an Optimized MDM2-Binding Peptide Selected with mRNA Display

Nagata, T., Shirakawa, K., Kobayashi, N., Shiheido, H., Tabata, N., Sakuma-Yonemura, Y., Horisawa, K., Katahira, M., Doi, N., & Yanagawa, H. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109163 · Cited by 20

Indolo‐pyrido‐isoquinolin based alkaloid inhibits growth, invasion and migration of breast cancer cells via activation of p53‐miR34a axis

Avtanski, D. B., Nagalingam, A., Tomaszewski, J. E., Risbood, P. A., Difilippantonio, M. J., Saxena, N. K., Malhotra, S. V., & Sharma, D. (2016) · Molecular Oncology · doi:10.1016/j.molonc.2016.04.003 · Cited by 20

Transcription factorIRX5 promotes hepatocellular carcinoma proliferation and inhibits apoptosis by regulating the p53 signalling pathway

Zhu, L., Dai, L., Yang, N., Liu, M., Ma, S., Li, C., Shen, J., Lin, T., Wang, D., Pan, W., et al. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3517 · Cited by 20

Structure- and Ligand-Based Virtual Screening Identifies New Scaffolds for Inhibitors of the Oncoprotein MDM2

Houston, D. R., Yen, L.-H., Pettit, S. B., & Walkinshaw, M. D. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121424 · Cited by 20

A Fluorescent-Based High-Throughput Screening Assay for Small Molecules That Inhibit the Interaction of MdmX with p53

Tsuganezawa, K., Nakagawa, Y., Kato, M., Taruya, S., Takahashi, F., Endoh, M., Utata, R., Mori, M., Ogawa, N., Honma, T., et al. (2012) · SLAS DISCOVERY · doi:10.1177/1087057112460729 · Cited by 19

Mouse models of Mdm2 and Mdm4 and their clinical implications

Xiong, S. (2013) · 癌症：英文版 · doi:10.5732/cjc.012.10286 · Cited by 19

Regio- and diastereoselective construction of a new set of functionalized pyrrolidine, spiropyrrolidine and spiropyrrolizidine scaffolds appended with aryl- and heteroaryl moieties via the azomethine ylide cycloadditions

Rajkumar, V., Babu, S. A., & Padmavathi, R. (2016) · Tetrahedron · doi:10.1016/j.tet.2016.07.053 · Cited by 19

Molecular hybridization-guided 1,3-dipolar cycloaddition reaction enabled pyrimidine-fused spiropyrrolidine oxindoles synthesis as potential anticancer agents

Liu, X., Feng, T., Jiang, W., Yang, C., Tian, M., Jiang, Y., Lin, B., Zhao, Z., & Zhou, Y. (2016) · Tetrahedron Letters · doi:10.1016/j.tetlet.2016.08.063 · Cited by 19

Chrysophanol, an anthraquinone from AST2017-01, possesses the anti-proliferative effect through increasing p53 protein levels in human mast cells

Han, N., Kim, H.-Y., Kang, S., Kim, M. H., Moon, P., Moon, P., Kim, H., & Jeong, H. (2019) · Inflammation Research · doi:10.1007/s00011-019-01239-7 · Cited by 19

Tandem aza-Michael/spiro-ring closure sequence: access to a versatile scaffold and total synthesis of (±)-coerulescine

Görmen, M., Goff, R. L., Lawson, A. M., Daı̈ch, A., & Comesse, S. (2013) · Tetrahedron Letters · doi:10.1016/j.tetlet.2013.02.047 · Cited by 19

The Molecular Docking of Flavonoids Isolated from Daucus carota as a Dual Inhibitor of MDM2 and MDMX

Muhammad, I., Rahman, N., Nayab, G. E., Niaz, S., Shah, M., Afridi, S. G., Khan, H. Z., Daglia, M., & Çapanoğlu, E. (2020) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/1574892815666200226112506 · Cited by 19

Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives

Kwok, M., Agathanggelou, A., Davies, N., & Stanković, T. (2021) · Cancers · doi:10.3390/cancers13184681 · Cited by 20

A Comparative Evaluation of the Cytotoxic and Antioxidant Activity of Mentha crispa Essential Oil, Its Major Constituent Rotundifolone, and Analogues on Human Glioblastoma

Türkez, H., Tozlu, Ö. Ö., Lima, T. C., de Brito, A. E. M., & de Sousa, D. P. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/2083923 · Cited by 19

New targets for the treatment of follicular lymphoma

Tageja, N., Padheye, S., Dandawate, P. R., Al-Katib, A. M., & Mohammad, R. M. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-50 · Cited by 20

Nutlin-3 induces BCL2A1 expression by activating ELK1 through the mitochondrial p53-ROS-ERK1/2 pathway

Lee, S., Choi, H. C., Choe, Y.-J., Shin, S. J., Lee, S. H., & Kim, H. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2463 · Cited by 18

Evolution of Conformational Disorder & Diversity of the P53 Interactome

Huart, A.-S., & Hupp, T. R. (2013) · Biodiscovery · doi:10.7750/biodiscovery.2013.8.5 · Cited by 18

Small-molecule modulation of p53 protein-protein interactions

Kuusk, A., Boyd, H., Chen, H., & Ottmann, C. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0405 · Cited by 18

Synthesis and Biological Evaluation of S-, O- and Se-Containing Dispirooxindoles

Kukushkin, M. E., Novotortsev, V. M., Filatov, V., Ivanenkov, Y. A., Skvortsov, D. A., Veselov, M. S., Shafikov, R. R., Moiseeva, A. A., Zyk, N., Majouga, A. G., et al. (2021) · Molecules · doi:10.3390/molecules26247645 · Cited by 18

MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?

Hav, M., Libbrecht, L. J., Ferdinande, L., Pattyn, P., Laurent, S., Peeters, M., Praet, M. M., & Pauwels, P. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-1012-7 · Cited by 18

Spiro-oxindole derivative 5-chloro-4′,5′-diphenyl-3′-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2′-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function

Saxena, R., Gupta, G., Manohar, M., Debnath, U., Popli, P., Prabhakar, Y. S., Konwar, R., Kumar, S., Kumar, A., & Dwivedi, A. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.11.003 · Cited by 18

Inhibitory Effects of Trehalose on Malignant Melanoma Cell Growth: Implications for a Novel Topical Anticancer Agent on the Ocular Surface

Kudo, T., Takeuchi, K., Ebina, Y., & Nakazawa, M. (2012) · ISRN Ophthalmology · doi:10.5402/2012/968493 · Cited by 18

An update patent review of MDM2–p53 interaction inhibitors (2019–2023)

Twarda‐Clapa, A. (2024) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2024.2419836 · Cited by 17

Highly Stereoselective Domino Oxa‐Michael/Aza‐Michael/Cyclization: Synthesis of Bicyclic Lactams and Spirooxindole Skeleton

Goff, R. L., Sanselme, M., Lawson, A. M., Daı̈ch, A., & Comesse, S. (2015) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201501072 · Cited by 17

Upregulation of p53 through induction of MDM2 degradation: Anthraquinone analogs

Draganov, A. B., Yang, X., Anifowose, A., Cruz, L. K. D. L., Dai, C., Ni, N., Chen, W., Santos, Z. A. D. L., Gu, L., Zhou, M., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.07.019 · Cited by 17

Recent advances in the pharmacological targeting of ubiquitin-regulating enzymes in cancer

Montagut, A. M., Armengol, M., Gorjón-de-Pablo, G., Estrada‐Tejedor, R., Borrell, J. I., & Roué, G. (2022) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2022.02.007 · Cited by 17

Dipolarophile-Controlled Regioselective 1,3-Dipolar Cycloaddition: A Switchable Divergent Access to Functionalized N-Fused Pyrrolidinyl Spirooxindoles

Wang, Y., Yan, L., Yan, Y., Li, S., Lu, H., Liu, J., & Dong, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043771 · Cited by 17

Understanding Small‐Molecule Binding to MDM2: Insights into Structural Effects of Isoindolinone Inhibitors from NMR Spectroscopy

Riedinger, C., Noble, M. E. M., Wright, D. J., Mulks, F. F., Hardcastle, I. R., Endicott, J., & McDonnell, J. M. (2011) · Chemical Biology & Drug Design · doi:10.1111/j.1747-0285.2011.01091.x · Cited by 17

Identification of novel inhibitors of p53–MDM2 interaction facilitated by pharmacophore-based virtual screening combining molecular docking strategy

Wang, W., Zhu, X., Hong, X., Zheng, L., Zhu, H., & Hu, Y. (2012) · MedChemComm · doi:10.1039/c2md20208e · Cited by 17

A Cell-Based High-Throughput Assay for the Screening of Small-Molecule Inhibitors of p53–MDM2 Interaction

Li, J., Zhang, S., Gao, L., Chen, Y., & Xie, X. (2011) · SLAS DISCOVERY · doi:10.1177/1087057111399191 · Cited by 17

Anti-cancer Potential of Captopril and Botulinum Toxin Type-A and Associated p53 Gene Apototic Stimulating Activity.

Shebl, R. I. (2019) · PubMed Central · doi:10.22037/ijpr.2019.1100800 · Cited by 17

MDMX in Cancer: A Partner of p53 and a p53-Independent Effector

Wu, L., Yan, Y., Huang, Q., & Zheng, D. (2024) · Biologics · doi:10.2147/btt.s436629 · Cited by 17

Expanding the horizon of chemotherapeutic targets: From MDM2 to MDMX (MDM4)

Macchiarulo, A., Giacchè, N., Carotti, A., Moretti, F., & Pellicciari, R. (2011) · MedChemComm · doi:10.1039/c0md00238k · Cited by 16

Effects of Spiro-bisheterocycles on Proliferation and Apoptosis in Human Breast Cancer Cell Lines

Ramdani, L. H., Talhi, O., Taïbi, N., Delort, L., Decombat, C., Silva, A. M. S., Bacharı, K., Vasson, M., & Caldefie‐Chezet, F. (2016) · Anticancer Research · doi:10.21873/anticanres.11237 · Cited by 16

Apamin as a Template for Structure‐Based Rational Design of Potent Peptide Activators of p53

Li, C., Pazgier, M., Liu, M., Lu, W., & Lu, W. (2009) · Angewandte Chemie · doi:10.1002/ange.200904550 · Cited by 16

Green oxidative rearrangement of indoles using halide catalyst and hydrogen peroxide

Wang, J., Chen, Y., Du, W., Chen, N., Fu, K., He, Q., & Shao, L. (2022) · Tetrahedron · doi:10.1016/j.tet.2022.133101 · Cited by 15

Engaging Isatins and Amino Acids in Multicomponent One-Pot 1,3-Dipolar Cycloaddition Reactions—Easy Access to Structural Diversity

Zhao, H., & Zhao, Y. (2023) · Molecules · doi:10.3390/molecules28186488 · Cited by 15

Base-Promoted Formal (3 + 2) Cycloaddition of α-Halohydroxamates with Electron-Deficient Alkenyl-iminoindolines To Synthesize Spiro-indolinepyrrolidinones

Zhang, X., Dai, H.-Y., Liu, W.-C., Zeng, R., Dai, Z. X., Wang, Y., Li, J., Li, Q., & Han, B. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.3c01619 · Cited by 15

Ring-opening hydrolysis of spiro-epoxyoxindoles using a reusable sulfonic acid functionalized nitrogen rich carbon catalyst

Patel, P., Tak, R. K., Parmar, B., Dabas, S., Patel, B., Suresh, E., Khan, N. H., & Subramanian, S. (2021) · RSC Advances · doi:10.1039/d1ra01161h · Cited by 15

Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system

Amaral, J. D., Herrera, F., Rodrigues, P. M., Dionísio, P. A., Outeiro, T. F., & Rodrigues, C. M. P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.12.009 · Cited by 15

Relative apoptotic potential and specific G1 arrest of stigmasterol and cinnamic acid isolated from the brown algae Padina gymnospora in HeLa and A549 cells

Sali, V. K., Mansingh, D. P., & Vasanthi, H. R. (2016) · MedChemComm · doi:10.1039/c6md00178e · Cited by 17

Organo‐Cascade Catalysis: Application of Merged Iminium‐Enamine Activation Technique and Related Cascade Reactivities

Mukherjee, S., & Biswas, B. (2020) · ChemistrySelect · doi:10.1002/slct.202003070 · Cited by 15

MD-4251: A First-in-Class Oral MDM2 Degrader Inducing Complete Tumor Regression with Single-Dose Administration

Acharyya, R. K., Huang, L., Aguilar, A., Hu, B., Bai, L., Metwally, H., McEachern, D., Jiang, W., Wang, Y., Li, Q., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00809 · Cited by 15

1,3‐Dipolar Cycloaddition of 3‐Chromonyl‐Substituted Glycine Imino Esters with Arylidenes and in situ Diastereodivergent via Retrocycloaddition

Radwan, M. F., Elboray, E. E., Dardeer, H. M., Kobayashi, Y., Furuta, T., Hamada, S., Dohi, T., & Aly, M. F. (2023) · Chemistry - An Asian Journal · doi:10.1002/asia.202300215 · Cited by 15

Cinchona Alkaloid‐Catalyzed Enantioselective Direct Aldol Reaction of N‐Boc‐Oxindoles with Polymeric Ethyl Glyoxylate

Pesciaioli, F., Righi, P., Mazzanti, A., Gianelli, C., Mancinelli, M., Bartoli, G., & Bencivenni, G. (2011) · Advanced Synthesis & Catalysis · doi:10.1002/adsc.201100499 · Cited by 14

Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells

Blagosklonny, M. V. (2012) · Oncotarget · doi:10.18632/oncotarget.548 · Cited by 14

Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3

Boyarskikh, U. A., Pintus, S. S., Mandrik, N., Stelmashenko, D., Kiselev, I. N., Evshin, I., Sharipov, R., Stegmaier, P., Kolpakov, F., Филипенко, М. Л., et al. (2018) · BMC Medical Genomics · doi:10.1186/s12920-018-0330-5 · Cited by 14

Two Birds with One Stone: NFAT1-MDM2 Dual Inhibitors for Cancer Therapy

Wang, W., Zafar, A., Rajaei, M., & Zhang, R. (2020) · Cells · doi:10.3390/cells9051176 · Cited by 14

exo′‐Selective Construction of Spirobipyrrolidines by the Silver‐catalyzed Asymmetric [3+2] Cycloaddition of Imino Esters with 4‐Benzylidene‐2,3‐dioxopyrrolidines

Furuya, S., Kanemoto, K., & Fukuzawa, S. (2022) · Chemistry - An Asian Journal · doi:10.1002/asia.202200239 · Cited by 14

Enantioselective construction of novel chiral spirooxindoles incorporating a thiazole nucleus

Cui, L.-Y., Wang, Y., & Zhou, Z. (2016) · RSC Advances · doi:10.1039/c6ra14178a · Cited by 14

Diastereoselective tandem oxidation/Michael/aldol reaction: unprecedented formation of dispirocyclopentanebisoxindoles and dispiro[acenaphthylene-1,1′-cyclopentane-3′,1′′-acenaphthylene]-2,2′′diones

Suman, K., Mala, R., & Thennarasu, S. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c6ob02607a · Cited by 14

Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells

Samudio, I. J., Duvvuri, S. R., Clise-Dwyer, K., Watt, J. C., Mak, D. H. F., Kantarjian, H. M., Yang, D., Ruvolo, V. R., & Borthakur, G. M. (2010) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428191003731325 · Cited by 16

Upregulation of p53 through induction of MDM2 degradation: Amino acid prodrugs of anthraquinone analogs

Anifowose, A., Yuan, Z., Yang, X., Pan, Z., Zheng, Y., Zhang, Z., & Wang, B. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.126786 · Cited by 14

Targeting biologically specific molecules in triple negative breast cancer (TNBC)

Mir, M. A., Sofi, S., & Qayoom, H. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-96136-3.00002-9 · Cited by 13

Searching for Dual Inhibitors of the MDM 2‐p53 and MDMX ‐p53 Protein–Protein Interaction by a Scaffold‐Hopping Approach

Zaytsev, A. V., Dodd, B., Magnani, M., Ghiron, C., Golding, B. T., Griffin, R. J., Liu, J., Lü, X., Micco, I., Newell, D. R., et al. (2014) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12474 · Cited by 13

Identification of insulin-sensitizing molecules acting by disrupting the interaction between the Insulin Receptor and Grb14

Gondoin, A., Hampe, C., Eudes, R., Fayolle, C., Pierre‐Eugène, C., Miteva, M. A., Villoutreix, B. O., Charnay‐Pouget, F., Aitken, D. J., Issad, T., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-17122-6 · Cited by 13

MDM4 expression as an indicator of TP53 reactivation by combined targeting of MDM2 and MDM4 in cancer cells without TP53 mutation

Hirose, M., Yamato, K., Endo, S., Saito, R., Ueno, T., Hirai, S., Suzuki, H., Abei, M., Natori, Y., & Hyodo, I. (2014) · Oncoscience · doi:10.18632/oncoscience.103 · Cited by 14

[3+2] Cycloaddition mediated synthesis of spirooxindole pyrrolidine/piperidine fused chromene aldehyde derivatives: DFT studies, antibacterial evaluation and molecular docking investigation as DNA gyrase inhibitors

Panda, J., Raiguru, B. P., Nayak, S., Mohapatra, S., Mohapatra, S., Rout, S., Mohanty, P., Biswal, H. S., Bhattacharya, D., & Sahoo, C. R. (2024) · New Journal of Chemistry · doi:10.1039/d4nj01102c · Cited by 12

Present and Future Prospect of Small Molecule & Related Targeted Therapy Against Human Cancer.

Pathak, A., Tanwar, S., Kumar, V., & Banarjee, B. D. (2018) · PubMed · Cited by 13

MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors

Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 12

Molecular Interaction Fields and 3D-QSAR Studies of p53−MDM2 Inhibitors Suggest Additional Features of Ligand−Target Interaction

Dezi, C., Carotti, A., Magnani, M., Baroni, M., Padova, A., Cruciani, G., Macchiarulo, A., & Pellicciari, R. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100113p · Cited by 12

Structural effects and competition mechanisms targeting the interactions between p53 and MDM2 for cancer therapy

Liu, S., Geng, Y.-Z., & Yan, S. (2017) · Frontiers of Physics · doi:10.1007/s11467-017-0667-9 · Cited by 12

Regioselective synthesis of spiro isoxazole‐oxindole‐tetrahydrothiophene hybrids via cascade reactions under catalyst‐free conditions

Nagaraju, S., Sathish, K., Satyanarayana, N., Paplal, B., & Kashinath, D. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3803 · Cited by 12

S100A1 blocks the interaction between p53 and mdm2 and decreases cell proliferation activity

Dowarha, D., Chou, R., & Yu, C. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234152 · Cited by 12

Differential regulation of p21 waf1 protein half-life by DNA damage and Nutlin-3 in p53 wild-type tumors and its therapeutic implications

Chang, L.-J., & Eastman, A. R. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.21047 · Cited by 12

Construction of highly enantioenriched spirocyclopentaneoxindoles containing four consecutive stereocenters via thiourea-catalyzed asymmetric Michael–Henry cascade reactions

Du, Y., Li, J., Chen, K., Wu, C., Zhou, Y., & Liu, H. (2017) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.13.131 · Cited by 12

MDM2/MDMX inhibitor peptide: WO2008106507

Macchiarulo, A., & Pellicciari, R. (2009) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543770902755137 · Cited by 12

Organocatalyzed Asymmetric Michael Addition of 3-Fluorooxindole to Vinylidene Bisphosphonates

Jin, Y., Wang, X., Ning, L.-W., Wang, R.-J., Li, Y., Zhang, Y., & Chen, L. (2024) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.4c00289 · Cited by 12

Design of Murine Double Minute 2 Proteolysis Targeting Chimera Degraders with a Built-In Tumor-Targeting Ability

Wang, Z., Yue, S., Chen, X., Li, J., Zhu, P., Chen, H., Qiu, F., Xie, D., Liang, Y., Li, D., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01228 · Cited by 11

FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index

Yau, C. S. F., Meyer, L. R., Benz, S. C., Vaske, C. J., Scott, G. K., Egan, B. S., Labhart, P., Pourmand, N., & Benz, C. C. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3589-7 · Cited by 11

Catalytic Enantioselective Synthesis of Spirooxindoles by Oxidative Rearrangement of Indoles

Qian, C., Li, P., & Sun, J. (2020) · Angewandte Chemie · doi:10.1002/ange.202015175 · Cited by 11

Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia

Sekiguchi, N., Kasahara, S., Miyamoto, T., Kiguchi, T., Ohno, H., Takagi, T., Tachibana, M., Sumi, H., Kakurai, Y., Yamashita, T., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03464-z · Cited by 11

CopA3 peptide inhibits MDM2-p53 complex stability in colorectal cancers and activates p53 mediated cell death machinery

Dey, D. K., Sharma, C., Vadlamudi, Y., & Kang, S. C. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121476 · Cited by 11

An Efficient and Easy Method for the One‐pot Synthesis of Spirooxindoles in the Presence of Na2CO3

Basha, K. N. U., & Shanthi, G. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3580 · Cited by 12

Apoptosis and cancer: insights molecular mechanisms and treatments

Iqbal, Z., Ataur Rahman*, M., Tipu Sultan, M., & Rokibul Islam, M. (2015) · Figshare · doi:10.6084/m9.figshare.1396210 · Cited by 11

Small-molecule approach to block p53-MDM2 interaction as a cancer therapeutic strategy

Wang, S. (2008) · Cancer Research

A novel orally active MDM2 inhibitor (MI-219) activates the p53 pathway and is selectively toxic to tumor cells

Shangary, S. K., Qin, D., McEachern, D., Miller, R. S., Nikolovska‐Coleska, Z., Liu, M., Qiu, S., Ding, K., Wang, G., Chen, J., et al. (2007) · Molecular Cancer Therapeutics · Cited by 1

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532

Small-Molecule Inhibitors of the MDM2-p53 Protein-Protein Interaction to Reactivate p53 Function: A Novel Approach for Cancer Therapy

Shangary, S., & Wang, S. (2009) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094723 · Cited by 623